Validating early post–transplant outcomes reported for recipients of deceased donor kidney transplants

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2016, Pages 324-331

  Potluri, Vishnu S ^a   Parikh, Chirag R ^b,c,d   Hall, Isaac E ^b,c   Ficek, Joseph ^b   Doshi, Mona D ^e   Butrymowicz, Isabel ^b   Weng, Francis L ^f   Schrӧppel, Bernd ^g   Thiessen Philbrook, Heather ^h   Reese, Peter P ⁱ  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Department of Medicine ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f SAINT BARNABAS MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute rejection; Adult; Allografts; Deceased donors; Delayed graft function; Humans; Kidney transplantation; Tissue and organ procurement; Tissue donors; Validation studies

Indexed keywords

PANEL REACTIVE ANTIBODY; BIOLOGICAL MARKER; CREATININE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ACUTE DISEASE; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; FACTUAL DATABASE; GRAFT REJECTION; HEALTH CARE QUALITY; HEMODIALYSIS; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES; VALIDATION STUDY;

ACUTE DISEASE; ADULT; BIOMARKERS; CREATININE; DATABASES, FACTUAL; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84957081247     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06950615     Document Type: Article

References (32)

1. DickinsonDM, Bryant PC, WilliamsMC, LevineGN, Li S,Welch JC, Keck BM,Webb RL: Transplant data: Sources, collection, and caveats. Am J Transplant 4[Suppl 9]: 13-26, 2004.
2. AxelrodDA, Lentine KL, XiaoH, Bubolz T, GoodmanD, Freeman R, Tuttle-Newhall JE, SchnitzlerMA: Accountability for end-stage organ care: Implications of geographic variation in access to kidney transplantation. Surgery 155: 734-742, 2014.
3. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S: Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: An analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 56: 1127-1139, 2010.
4. Locke JE, James NT,Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, Montgomery RA, Segev DL: Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation 97: 446-450, 2014.
5. Mohan S, Tanriover B, Ali N, Crew RJ, Dube GK, Radhakrishnan J, Hardy MA, Ratner LE, McClellan W, Cohen D: Availability, utilization and outcomes of deceased diabetic donor kidneys; analysis based on the UNOS registry. Am J Transplant 12: 2098-2105, 2012.
6. Simpkins CE, Montgomery RA, Hawxby AM, Locke JE, Gentry SE, Warren DS, Segev DL: Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible? Am J Transplant 7: 99-107, 2007.
7. Tanriover B, Zhang S,MacConmara M,Gao A, Sandikci B, Ayvaci MU, Mete M, Tsapepas D, Rajora N, Mohan P, Lakhia R, Lu CY, Vazquez M: Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clin J Am Soc Nephrol 10: 1041-1049,2015.
8. Mallon DH, Summers DM, Bradley JA, Pettigrew GJ: Defining delayed graft function after renal transplantation: Simplest is best. Transplantation 96: 885-889, 2013.
9. Israni AK, Li N, Cizman BB, Snyder J, Abrams J, JoffeM, Rebbeck T, Feldman HI: Association of donor inflammation- and apoptosisrelated genotypes and delayed allograft function after kidney transplantation. Am J Kidney Dis 52: 331-339, 2008.
10. GillespieBW, MerionRM, Ortiz-Rios E, Tong L, Shaked A, Brown RS, Ojo AO, Hayashi PH, Berg CL, Abecassis MM, Ashworth AS, Friese CE, Hong JC, Trotter JF, Everhart JE; A2ALL Study Group: Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant 10: 1621-1633, 2010.
11. Goldberg D, French B, Trotter J, Shetty K, Schiano T, Reddy KR, Halpern SD: Underreporting of liver transplant waitlist removals due to death or clinical deterioration: Results at four major centers. Transplantation 96: 211-216, 2013.
12. Stirnemann PM, Takemoto SK, Schnitzler MA, Brennan DC, Abbott KC, Salvalaggio P, Burroughs TE, Gavard JA, Willoughby LM, Lentine KL: Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J AmSoc Nephrol 17: 2299-2306, 2006.
13. Machnicki G, Pinsky B, Takemoto S, Balshaw R, Salvalaggio PR, Buchanan PM, Irish W, Bunnapradist S, Lentine KL, Burroughs TE, Brennan DC, Schnitzler MA: Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant 9: 494-505, 2009.
14. US National Institutes of Health: Deceased Donor Biomarkers and Recipient Outcomes (DDS): 2013. Available at: https:// clinicaltrials.gov/ct2/show/NCT01848249. Accessed August 23,2015.
15. Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS): Organ procurement and transplantation network. Final rule. Fed Regist 78:40033-40042, 2013.
16. Messa P, Ponticelli C, Berardinelli L: Coming back to dialysis after kidney transplant failure. Nephrol Dial Transplant 23: 2738-2742, 2008.
17. Altman DG, Bland JM: Diagnostic tests. 1: Sensitivity and specificity. BMJ 308: 1552, 1994.
18. Gordis L: Epidemiology, Philadelphia, W.B. Saunders, 1996.
19. Agresti A: Categorical Data Analysis, Hoboken, NJ, Wiley, 2013.
20. Organ Procurement and Transplantation Network: A Guide to Calculating and Interpreting the Kidney Donor Profile Index (KDPI). Available at: http://optn.transplant.hrsa.gov/ContentDocuments/ Guide_to_Calculating_Interpreting_KDPI.pdf. Accessed August 21, 2015.
21. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, Port FK, Sung RS: A comprehensive risk quantification score for deceased donor kidneys: The kidney donor risk index. Transplantation 88: 231-236, 2009.
22. Organ Procurement and Transplantation Network: Organ Procurement and Transplantation Network Policies: Policy 18. Data Submission Requirements. Available at: http://optn.transplant. hrsa.gov/ContentDocuments/OPTN_Policies.pdf#nameddest= Policy_18. Accessed August 17, 2015.
23. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J: Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 57: 208-211, 1994.
24. Scholten EM, Rowshani AT, Cremers S, Bemelman FJ, Eikmans M, van Kan E, Mallat MJ, Florquin S, Surachno J, ten Berge IJ, Bajema IM, de Fijter JW: Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 17: 2622-2632, 2006.
25. Shapiro R, Jordan ML, Scantlebury VP, Vivas CA, Jain A, McCauley J, Egidi MF, Randhawa P, Chakrabarti P, Corry RJ: Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: Does dissynchronous rejection really exist? Transplantation 69: 440-441, 2000.
26. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR: Mycophenolate mofetil combination therapy improves longterm outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 11: 750-759, 2005.
27. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group: Rabbit antithymocyte globulin versus basiliximab in renal transplantation.NEngl J Med 355: 1967-1977, 2006.
28. Brennan DC, Schnitzler MA: Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359: 1736-1738, 2008.
29. Wiesner RH, Steffen BJ, David KM, Chu AH, Gordon RD, Lake JR: Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant 6: 1609-1616, 2006.
30. Andreoni KA, Forbes R, Andreoni RM, Phillips G, Stewart H, Ferris M: Age-related kidney transplant outcomes: Health disparities amplified in adolescence. JAMA Intern Med 173: 1524-1532, 2013.
31. Levine MH, Reese PP,Wood A, Baluarte JH, Huverserian A, Naji A, Abt PL: Inferior allograft outcomes in adolescent recipients of renal transplants from ideal deceased donors. Ann Surg 255:556-564, 2012.
32. Kasiske BL, McBride MA, Cornell DL, Gaston RS, Henry ML, Irwin FD, Israni AK, Metzler NW, Murphy KW, Reed AI, Roberts JP, Salkowski N, Snyder JJ, Sweet SC: Report of a consensus conference on transplant program quality and surveillance. Am J Transplant 12: 1988-1996, 2012.